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Fig.1 Comparison between Fluka MC simulation (red line), 
dose distribution evaluated with CERR using Double 
Gaussian model (green line) and dose predicted by 
standalone computational model (blue line) for a proton 
initial beam energy of 60MeV, initial σ  of 0.4cm, at a 
normalized depth 0.9 (assuming Bragg peak position at 1) 
 
The preliminary results show that the model is able to 
predict dose with better accuracy than DGA. 
So, this model could be a step forward in lateral dose 
prediction for current TPS and as a future application, a 
useful tool for online dose-evaluation and adaptive 
planning; next step will be the implementation of different 
media and geometries. 
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Purpose: To define the clinical protocol for Head and Neck 
(H&N) patients treated with Proton Pencil Beam Scanning 
(PBS) at Paul Scherrer Institute (PSI, Villigen CH) with 
Simultaneous Integrated Boost (SIB). The focus was mainly to 
define the optimization parameters and the normalization 
procedure to obtain a steep gradient between the elective 
and the boost volume, in order to reduce over-dosage in the 
fall off area of the boost.  
Material and Methods: 7 patients, treated at PSI for different 
H&N carcinomas, were selected for this study. They were all 
originally treated with two sequential series at 2GyRBE;  the 
1st one up to 54GyRBE to the elective Planning Target Volume 
(PTV1), followed by a second series up to 72GyRBE for the 
boost target volume (PTV2). In this study, all have been re-
planned using a SIB regimen of 1.8GyRBE (up to 54GyRBE) to 
PTV1 and 2.36GyRBE (up to 70.8GyRBE) to PTV2 for a total of 
30 fractions. Dose constraints to the OARs were kept as for 
the sequential approach [1]. All plans were designed on the 
PSIPlan Treatment Planning System using Intensity Modulated 
Proton Therapy (IMPT) with non-coplanar fields. The 
prescription dose of 100% corresponded to the average dose 
to PTV1, while the dose to PTV2 was optimized prescribing a 
boosting factor based on the ratio of the two different 
prescribed dose levels (i.e. 54GyRBE and 70.8 GyRBE). 
Depending on the ratio of the PTV1 and PTV2 volumes the 
boosting factor was prescribed to PTV2 or to a smaller 
structure (GTV or PTV2-3mm). To guarantee dose 
homogeneity in the dose gradient region between PTV1 and 
PTV2, the optimized SIB plans were normalized such that 
54GyRBE corresponded to the average dose to [PTV1-(Boost 
volume+3mm)]. This avoided over-dosages close to PTV2 
being compensated by under-dosages at the PTV1 margin.  
Results:  The choice of the boosted volume, the boosting 
factor, the quality and conformity of the SIB plans were 
observed to be dependent on the volume ratio PTV2/PTV1. 
For the analyzed patients, this ranged from 28.8% to 61.7%. 
For differences in the PTV1 to PTV2 volume larger than 40%, 
either a PTV2-3mm or the GTV itself were selected for the 
boosting. Else no gradient could be observed. When 
compared to the nominal sequential plan, the SIB approach 
resulted in both a lower mean dose to the ring area (average 
value for SIB: 55.2+1.0 GyRBE; average value for sequential: 
64.1+3.6 GyRBE), and 0.6+0.4% as average ring volume 
receiving the 95% of the dose prescribed to the boost (the 
same dose parameter was >10% for all the original plans). A 
similar sparing of OARs was obtained with both treatment 
schedules. 
Conclusion:  Planning H&N patients with SIB optimization 
resulted in dose distributions which guaranteed the PTV2 and 
PTV1 coverage and conformity whilst keeping dose to OARs 
within tolerance. Therefore this approach can be transferred 
to the clinical operation and has already been applied to a 
first patient.  
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Gamma locator is a handheld lightweight and compact 
gamma probe based on a scintillation crystal LaBr3:Ce and 
silicone photomultiplier to be used for detection of gamma-
radiation emitted by radionuclides such as 99mTc, 125I, 111In, 18F 
[1]. 
There are two main applications of gamma locator: 
intraoperative detection of sentinel lymph nodes and non-
invasive scanning the surface of the body. In the first case, a 
radiotracer is injected into the patient preoperatively and 
